Quintiles Transitional Holdings Inc. (Q) PT Raised to $104.00

Quintiles Transitional Holdings Inc. (NYSE:Q) had its target price lifted by research analysts at Argus from $98.00 to $104.00 in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the medical research company’s stock. Argus’ price target points to a potential upside of 9.47% from the company’s previous close.

Other analysts also recently issued reports about the company. Citigroup Inc. restated a “neutral” rating and set a $96.00 price objective (up from $87.00) on shares of Quintiles Transitional Holdings in a research report on Wednesday, June 28th. Robert W. Baird upgraded Quintiles Transitional Holdings from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $76.00 to $93.00 in a research report on Friday, July 7th. Zacks Investment Research upgraded Quintiles Transitional Holdings from a “hold” rating to a “buy” rating and set a $101.00 price objective for the company in a research report on Thursday, July 27th. Credit Suisse Group restated an “outperform” rating and set a $96.00 price objective (up from $94.00) on shares of Quintiles Transitional Holdings in a research report on Tuesday, June 6th. Finally, Barclays PLC restated an “overweight” rating and set a $98.00 price objective (up from $90.00) on shares of Quintiles Transitional Holdings in a research report on Monday, July 17th. Eleven equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Quintiles Transitional Holdings has an average rating of “Buy” and an average target price of $92.44.

Quintiles Transitional Holdings (Q) opened at 95.00 on Monday. The company has a market capitalization of $20.57 billion, a PE ratio of 275.36 and a beta of 0.63. Quintiles Transitional Holdings has a 12-month low of $70.10 and a 12-month high of $99.95. The company has a 50 day moving average price of $93.80 and a 200-day moving average price of $86.86.

Quintiles Transitional Holdings (NYSE:Q) last released its earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.04. The company had revenue of $1.97 billion for the quarter, compared to analyst estimates of $1.96 billion. Quintiles Transitional Holdings had a return on equity of 14.23% and a net margin of 0.82%. Quintiles Transitional Holdings’s quarterly revenue was up 68.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.93 EPS. On average, analysts anticipate that Quintiles Transitional Holdings will post $4.58 EPS for the current year.

Quintiles Transitional Holdings declared that its Board of Directors has initiated a share buyback program on Wednesday, May 24th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 5.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/09/20/quintiles-transitional-holdings-inc-q-pt-raised-to-104-00.html.

In other news, insider Kevin C. Knightly sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $90.28, for a total transaction of $1,805,600.00. Following the completion of the transaction, the insider now directly owns 46,826 shares in the company, valued at $4,227,451.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Dennis B. Ph D. Gillings sold 968,023 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $97.33, for a total value of $94,217,678.59. Following the transaction, the director now owns 9,071,839 shares of the company’s stock, valued at $882,962,089.87. The disclosure for this sale can be found here. Insiders have sold 6,363,847 shares of company stock valued at $618,573,696 over the last 90 days. 6.40% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Quintiles Transitional Holdings by 2.2% during the second quarter. Vanguard Group Inc. now owns 12,789,723 shares of the medical research company’s stock worth $1,144,680,000 after acquiring an additional 280,893 shares during the last quarter. Glenview Capital Management LLC raised its position in shares of Quintiles Transitional Holdings by 29.3% during the second quarter. Glenview Capital Management LLC now owns 8,921,356 shares of the medical research company’s stock worth $798,461,000 after acquiring an additional 2,023,719 shares during the last quarter. Longview Partners Guernsey LTD raised its position in shares of Quintiles Transitional Holdings by 6.2% during the second quarter. Longview Partners Guernsey LTD now owns 8,711,447 shares of the medical research company’s stock worth $779,675,000 after acquiring an additional 505,526 shares during the last quarter. Janus Capital Management LLC raised its position in shares of Quintiles Transitional Holdings by 0.4% during the first quarter. Janus Capital Management LLC now owns 7,783,546 shares of the medical research company’s stock worth $626,804,000 after acquiring an additional 27,675 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Quintiles Transitional Holdings by 4,217.1% during the first quarter. BlackRock Inc. now owns 7,098,723 shares of the medical research company’s stock worth $571,660,000 after acquiring an additional 6,934,290 shares during the last quarter. Institutional investors own 91.34% of the company’s stock.

Quintiles Transitional Holdings Company Profile

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Analyst Recommendations for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply